BOEHRINGER INGELHEIM Overview
Upcoming Projects (BOEHRINGER INGELHEIM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BOEHRINGER INGELHEIM)
-
Digging into the breakthrough results from a survodutide Phase 2 trial sub-analysis in MASH and Liver Fibrosis
Tickers: BOEHRINGER INGELHEIM, ZEAL
Executed On: Jul 03, 2024 at 04:00 PM EDT -
Discussing the potential use of schizophrenia prescription digital therapeutics (PDT) with a close look at the CT-155 software from Boehringer Ingelheim and Click Therapeutics.
Tickers: BOEHRINGER INGELHEIM, Click Therapeutics
Executed On: Jun 04, 2024 at 11:00 AM EDT -
Discussing the potential of Boehringer's Survodutide in Biopsy-Confirmed F1/F2/F3 MASH with a focus on the Phase II MASH trial
Tickers: BOEHRINGER INGELHEIM, ZEAL
Executed On: Mar 28, 2024 at 11:30 AM EDT -
Reviewing the potential of Algernon Pharmaceutical's experimental lung disease drug, ifenprodil, for patients with IPF
Tickers: AGNPF, RHHBY, Boehringer Ingelheim
Executed On: Feb 22, 2023 at 11:00 AM EST
Expired Projects (BOEHRINGER INGELHEIM)
-
A look at the portfolio of emerging classes of obesity medications in early development
Tickers: BOEHRINGER INGELHEIM, AMGN, ZEAL, Gubra
Execute By: Oct 22, 2024
Upcoming & Overdue Catalysts (BOEHRINGER INGELHEIM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BOEHRINGER INGELHEIM)
-
Boehringer Ingelheim Announces Phase 3 Results for Humira Biosimilar Candidate in Active Rheumatoid Arthritis
Tickers: BOEHRINGER INGELHEIM, ABBV
Occurred on: Oct 26, 2016 -
Lilly (LLY) and Boehringer Ingelheim's Glyxambi Recommended for Approval by European Ad Comm for Type 2 Diabetes
Tickers: LLY, Boehringer Ingelheim
Occurred on: Sep 16, 2016 -
New Data: Spiolto Respimat significantly improves exercise capacity in people with COPD
Ticker: BOEHRINGER INGELHEIM
Occurred on: Sep 05, 2016 -
First Study Initiated to Evaluate the Effect of Ofev Treatment on Biomarkers that may Predict IPF Progression
Ticker: BOEHRINGER INGELHEIM
Occurred on: Jul 27, 2016 -
FDA approves Gilotrif (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung
Ticker: BOEHRINGER INGELHEIM
Occurred on: May 15, 2016 -
New Analyses: Adding SPIRIVA RESPIMAT Effective for Uncontrolled Asthma - Regardless of Allergy Subtype
Ticker: BOEHRINGER INGELHEIM
Occurred on: Mar 07, 2016 -
SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
Ticker: BOEHRINGER INGELHEIM
Occurred on: Feb 04, 2016 -
Boehringer Ingelheim's Praxbind Approved by FDA for Use As an Emergency Reversing Agent in Patients Taking Pradaxa
Tickers: BOEHRINGER INGELHEIM, PTLA, BXLT, PFE, BMY
Occurred on: Oct 16, 2015
Strategic Initiatives (BOEHRINGER INGELHEIM)
-
Lilly's (LLY) Elanco Unit Acquires Boehringer Ingelheim's Rabies Vaccine Portfolio for $885M
Tickers: LLY, Boehringer Ingelheim, Vetmedica, Elanco
Announcement Date: Oct 05, 2016 -
Lilly And Boehringer Ingelheim Announce Clinical Trial Collaboration In Metastatic Breast Cancer
Tickers: LLY, Boehringer Ingelheim
Announcement Date: Jul 13, 2016 -
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Tickers: ABBV, Boehringer Ingelheim
Announcement Date: Mar 07, 2016
